The analogue, liraglutide, was effective in clinical studies (the LEAD trials [16]) and was subsequently tested in a cardiovascular outcome trial, the LEADER trial [17], as demanded by the FDA for new antidiabetic agents
(2020) Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
We understand the emotional and physical challenges that can accompany weight loss, and our compassionate team is here to guide and support you throughout the process, ensuring that you feel empowered and confident in your decisions
Use it as a baseline, then rotate foods you tolerate well
In this review, we aim to (1) provide a comprehensive overview of the structure and regulation of CYP51A1, (2) highlight its diverse roles in cellular homeostasis and death pathways, and (3) discuss its translational potential as a therapeutic target